share_log

Investors in Shanghai Hile Bio-Technology (SHSE:603718) From Three Years Ago Are Still Down 44%, Even After 10% Gain This Past Week

Investors in Shanghai Hile Bio-Technology (SHSE:603718) From Three Years Ago Are Still Down 44%, Even After 10% Gain This Past Week

上海海利生物科技(SHSE:603718)的投資者從三年前開始仍然虧損44%,即使在過去一週中獲得了10%的增長。
Simply Wall St ·  10/05 21:28

While not a mind-blowing move, it is good to see that the Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) share price has gained 21% in the last three months. But that cannot eclipse the less-than-impressive returns over the last three years. Truth be told the share price declined 45% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.

儘管這並不是一個令人瞠目結舌的舉動,但值得一提的是,上海海利生物科技股份有限公司(SHSE:603718)股價在過去三個月內上漲了21%。但無法掩蓋在過去三年中不甚理想的回報。實話實說,股價在三年內下跌了45%,親愛的讀者,這種回報遠不及您從指數基金 passivetrade with an index fund 獲得的回報。

The recent uptick of 10% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近的10%上漲可能是未來好轉的積極信號,所以讓我們來看看歷史基本面。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

引用巴菲特的話:「船隻將周遊世界,而『地平派』仍會興旺。市場上的價格和價值仍會存在廣泛的差距……」考慮一家公司在市場上的認知如何變化的一個不完美但簡單的方法是比較每股收益(EPS)的變化和股價的波動。

Shanghai Hile Bio-Technology saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

上海海利生物科技在過去三年中股價下跌,同時每股收益也下降,陷入虧損。由於公司已經陷入虧損的境地,很難將每股收益的變化與股價的變化進行比較。但我們可以說,在這種情況下,我們預計會看到股價下跌。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖顯示了EPS隨時間變化的情況(點擊圖像以顯示確切值)。

big
SHSE:603718 Earnings Per Share Growth October 6th 2024
2024年10月6日的每股收益增長

It might be well worthwhile taking a look at our free report on Shanghai Hile Bio-Technology's earnings, revenue and cash flow.

您可能會發現我們關於上海海利生物的收入、營業收入和現金流的免費報告非常值得一看。

A Different Perspective

不同的觀點

Investors in Shanghai Hile Bio-Technology had a tough year, with a total loss of 30% (including dividends), against a market gain of about 3.3%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 7% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Shanghai Hile Bio-Technology is showing 1 warning sign in our investment analysis , you should know about...

上海海利生物的投資者經歷了艱難的一年,包括分紅在內,總損失達30%,而市場收益約爲3.3%。 但請記住,即使是最好的股票有時也會在十二個月內表現不佳。不幸的是,去年的表現可能表明存在未解決的挑戰,因爲它比過去半個世紀的年化損失7%更糟。我們意識到巴倫·羅斯柴爾德曾說過投資者應該在「街上有血的時候買入」,但我們警告投資者應首先確定他們正在購買優質的業務。我發現長期關注股價作爲業務表現的一種替代方式非常有趣。但要真正獲得洞察力,我們也需要考慮其他信息。即便如此,請注意,我們的投資分析顯示上海海利生物展示了1個警告信號,您應該了解...

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您願意查看另一家公司(具有潛在的更好財務狀況),請不要錯過這個免費的公司列表,證明它們可以增長收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論